As we mentioned yesterday (but of course, do your own due diligence here!), Lilly has been on a nice-heater, with the weight-loss franchises — and now it is set to market an oral weight loss challenger, to compete with Novo-, as early as Q2 2026.
That bodes well for Lilly though at least 2029. Here’s that blurb — and yes this is power alley stuff, but I don’t follow the weight loss drugs closely — as I am a lil’ concerned about potential longer-term side effects. [All of which we just haven’t seen the drugs on mass-market long enough — to really get a read-out on. Like over several hundred thousands of patients, over a decade, or more — and we are still about four years away from having that longitudinal data, post hoc.]
…After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the one arena it now dominates — oral therapeutics. But with Lilly preparing to launch its obesity pill orforglipron as early as the second quarter, can Novo’s grip on the oral market last?
This year got off to a rocky start for the Danish pharma giant. The company said last month it’s expecting a drop in sales and profits in 2026 as it faces federal pricing constraints, and fierce competition from Lilly and compounding pharmacies….
Now you know — from snow yesterday to mid-60s later today and bright sunshine! Welcome to Spring weather in the Rockies. Heh….
नमस्ते
Powerline Lies... 